Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    22453568 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)
Condition: Sarcoma
Interventions: Drug: imatinib mesylate;   Drug: imatinib

Indicates status has not been verified in more than two years